Drug Development, Immunization and White Paper

Alzheimer’s disease biomarkers galvanise rocky drug development space

Pharmaceutical Technology

DECEMBER 7, 2022

A Phase II study of the pharmacodynamic effects of semorinemab (RG 6100), an investigational drug being developed by Roche and AC Immune, on plasma and cerebrospinal fluid (CSF) also took into account plasma and CSF p-tau levels to determine individuals’ response to treatment. Please check your email to download the Report.

Drug Development

Drug Development Communication Immunity Immunization

Alzheimer’s disease biomarkers galvanize rocky drug development space

Pharmaceutical Technology

DECEMBER 7, 2022

A Phase II study of the pharmacodynamic effects of semorinemab (RG 6100), an investigational drug being developed by Roche and AC Immune, on plasma and cerebrospinal fluid (CSF) also took into account plasma and CSF p-tau levels to determine individuals’ response to treatment. Please check your email to download the Report.

Drug Development

Drug Development Communication Immunity Immunization

EC approves argenx’s efgartigimod alfa for CIDP treatment

Pharmaceutical Technology

JUNE 23, 2025

The European Commission (EC) has approved argenx’s Vyvgart (efgartigimod alfa) 1000mg as a single agent for subcutaneous injection to treat adults with chronic inflammatory demyelinating polyneuropathy (CIDP), an immune-mediated neuromuscular disorder of the peripheral nervous system.

Pharmaceutical Manufacturing

Pharmaceutical Manufacturing Communication Hospitals Packaging

Harbour BioMed partners Otsuka on new T-cell therapy

Pharmaceutical Technology

JUNE 23, 2025

June 23, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook HBM7020 activates immune system T cells to target and destroy B cells and plasma cells involved in many autoimmune diseases. Credit: luchschenF /Shutterstock.

Insurance Coverage and Processing

Insurance Coverage and Processing Communication Pharmaceutical Manufacturing Hospitals

Navigating uncertainty: the future of vaccine oversight amid CDC firings

Pharmaceutical Technology

JUNE 25, 2025

In a controversial move on 9 June 2025, US Secretary of Health and Human Services Robert F Kennedy Jr dismissed all 17 members of the Centers for Disease Control and Prevention (CDC) Advisory Committee for Immunization Practices (ACIP) that advises the federal government on vaccine safety.

Vaccines

Vaccines Hospitals Packaging Communication

Eucure Biopharma and Chipscreen NewWay sign licence deal for YH008

Pharmaceutical Technology

FEBRUARY 28, 2023

Biocytogen’s independently developed bispecific antibody, YH008, exerts antagonistic and agonistic activities. It was engineered with an Fc-silent IgG1 isotype to avoid activation of Fc-receptor-mediated non-specific immune. It also activated tumour-infiltrating DCs and T cells in vivo pharmacodynamic studies.

Immunity

Immunity Immunization Communication Drug Development

UCB and Cancer Research UK partner for oncology antibody candidates

Pharmaceutical Technology

MARCH 9, 2023

UCB4594 targets the immune checkpoint, human leukocyte antigen G, which is also called HLA-G. Under the partnership, the Centre for Drug Development of Cancer Research UK will appoint the chief clinical and scientific investigators.

Communication

Communication Immunity Immunization Drug Development

NSW government invests $13.39m in life-changing therapies

Pharmaceutical Technology

JUNE 20, 2025

Find out more This treatment involves obtaining immune cells from patients, modifying them in a laboratory setting then reintroducing them into patients’ bodies to destroy cancerous cells. Data Insights The gold standard of business intelligence. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate?

Insurance Coverage and Processing

Insurance Coverage and Processing Hospitals Communication Pharmaceutical Manufacturing

Race to the finish: pharma edges closer to approval with RSV vaccines

Pharmaceutical Technology

FEBRUARY 1, 2023

Pharmaceutical companies are pushing to develop drugs and vaccines for RSV with these populations in mind. Since the FDA approved AstraZeneca’s monoclonal antibody therapy Synagis (palivizumab) 25 years ago, drug development successes for RSV have been few and far between.

Vaccines

Vaccines Drug Development Pharmaceutical Companies Pharmaceutical Companies

Pharma Fix: The quest for the next tuberculosis vaccine

Pharmaceutical Technology

MARCH 24, 2023

In light of World TB day on March 24, the field hopes to overcome some major barriers to the drug development landscape. Unfortunately, lack of funding and resources remain an obstacle within the TB field for developing new vaccines. The BCG vaccine is a live-attenuated virus vaccine.

Vaccines

Vaccines Health and Personal Care Stores Immunity Immunization

FDA Commissioner envisions fewer delays, more clinical trial flexibility and AI use

Pharmaceutical Technology

JUNE 18, 2025

Reports Use of Artificial Intelligence in Pharmaceutical Drug Development a. fired 17 sitting members of the Advisory Committee on Immunization Practices at the Centers for Disease Control and Prevention (CDC), concerns rose about the stance of federal agencies on vaccines. Find out more Sign up for our daily news round-up!

Vaccines

Vaccines Communication Hospitals Drug Development

Meet the company on a mission to transform research and advance healthcare

Pharmaceutical Technology

FEBRUARY 20, 2023

On the other hand, a lack of diversity in clinical trial populations, particularly when the disease population is significantly underrepresented, greatly diminishes the quality of data obtained for drug safety and efficacy profiles. This may sound obvious, but it is still a major hurdle in drug development.

Vaccines

Vaccines Communication Immunity Immunization